1. HBW Insight
  2. >>Geography
  3. >>Latin America

J&J Consumer Business Expansion On Table After Consent Decree Obligations End

 
• By Elizabeth Crawford

J&J is “very excited about the possibility of consumer becoming a bigger part of our business,” CFO Caruso says, noting it hopes to grow the business organically and through acquisitions. But J&J first must complete its obligations under a consent decree related to manufacturing quality problems.

Johnson & Johnson is looking for opportunities to expand its consumer business after it satisfies an FDA consent decree and fully restores distribution of all of its OTC brands affected by manufacturing quality control problems.

“We are very excited about the possibility of consumer becoming a bigger part of our business,” J&J Chief Financial Officer...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Latin America

Bayer Consumer Health Expands North America And LATAM Supply Capacity

Bayer is investing $52m in its Lerma, Mexico manufacturing site, which the firm said will enable it to increase production of key OTC brands like Aspirin and Alka-Seltzer from 100m to 140m units by 2030.

Perrigo Q2 Results Down Nearly 11% On Formula Slump Despite Women’s Health Sales Jump On Opill

 
• By Malcolm Spicer

OTC private label/store brand product giant’s Q2 net sales down 10.7% to $1.1bn, but women’s health product sales jump 31.4% largely on Opill launched late in Q1. Biggest hit to results from infant formula business, down a reported 82% due to ongoing manufacturing quality-control remediation.

Opill Launch Delivers For Perrigo While Growing Pains Slow Overall First-Quarter Results

 
• By Malcolm Spicer

Perrigo spares little about Opill’s launch, advertising and outlook in Q1 earnings briefing, but management also makes clear it’s a large firm and some other segments of its global consumer health products business are holding back overall results.

Herbalife's Rising Digital Platform Floats All Boats Other Than Marketing To GLP-1 Patients

 
• By Malcolm Spicer

Direct seller reports Q1 sales up 1% to $1.3bn but net sales off 17.1% from year-ago period to $24.3m. Its distributor ranks jumped so far in 2024, particularly in China, where changes were made in the past year including new company leadership.

More from Geography

Over The Counter: EU Omnibus And ESG, What You Need To Know, With CEN Group’s Jasper Crone

 
• By David Ridley

HBW Insight catches up with sustainability expert Jasper Crone to find out what consumer health companies need to know about the European Commission's Omnibus simplification package.

AESGP Annual Meeting: European OTC Market Outlook ‘Very Positive’ Thanks To Prevention Trend

 
• By David Ridley

The European OTC market grew at double the rate of the global market in the last twelve months, according to IQVIA Consumer Health, driven by a long-term trend for prevention. Consultancy Simon Kucher identifies a desire to live a longer, healthier life as the primary concern behind this trend.

AESGP Annual Meeting: Harmonizing EU VMS Max Levels Could Cost Sector Over €200m

 
• By David Ridley

Limited capacity and a two-to-three year timescale for reformulation could mean that many VMS supplements disappear from the market, warns EPPA partner Alexandra Bocquillion, speaking at the AESGP Annual Meeting in Warsaw, Poland.